CN113710695A - 低氧反应性嵌合抗原受体 - Google Patents

低氧反应性嵌合抗原受体 Download PDF

Info

Publication number
CN113710695A
CN113710695A CN202080029850.8A CN202080029850A CN113710695A CN 113710695 A CN113710695 A CN 113710695A CN 202080029850 A CN202080029850 A CN 202080029850A CN 113710695 A CN113710695 A CN 113710695A
Authority
CN
China
Prior art keywords
nucleic acid
cells
cell
car
hypoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080029850.8A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·诺布尔·阿诺德
约翰·马赫
帕拉斯凯瓦斯·科斯蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of CN113710695A publication Critical patent/CN113710695A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
CN202080029850.8A 2019-02-19 2020-02-19 低氧反应性嵌合抗原受体 Pending CN113710695A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902277.1 2019-02-19
GBGB1902277.1A GB201902277D0 (en) 2019-02-19 2019-02-19 Therapeutic agents
PCT/GB2020/050401 WO2020169974A1 (en) 2019-02-19 2020-02-19 Hypoxia-responsive chimeric antigen receptors

Publications (1)

Publication Number Publication Date
CN113710695A true CN113710695A (zh) 2021-11-26

Family

ID=65998727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080029850.8A Pending CN113710695A (zh) 2019-02-19 2020-02-19 低氧反应性嵌合抗原受体

Country Status (11)

Country Link
US (1) US20220195009A1 (https=)
EP (1) EP3927734A1 (https=)
JP (1) JP7684692B2 (https=)
KR (1) KR20210132105A (https=)
CN (1) CN113710695A (https=)
AU (1) AU2020224373B2 (https=)
BR (1) BR112021016435A2 (https=)
CA (1) CA3130688A1 (https=)
GB (1) GB201902277D0 (https=)
IL (1) IL285587A (https=)
WO (1) WO2020169974A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025016333A1 (zh) * 2023-07-14 2025-01-23 广州百吉生物制药有限公司 一种工程化免疫细胞及其制备和应用
CN119491023A (zh) * 2024-12-03 2025-02-21 北京再生世纪生物科技有限公司 一种基因修饰增强脐带间充质干细胞旁分泌功能的方法及其应用
WO2026016166A1 (zh) * 2024-07-19 2026-01-22 上海鑫湾生物科技有限公司 一种响应缺氧环境的差异化基因表达调控系统及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922721A4 (en) * 2019-03-12 2023-01-11 Chongqing Precision Biotech Company Limited PROMOTER REGULATED BY HYPOXIA AND ITS APPLICATION
JP2024530215A (ja) * 2021-08-13 2024-08-16 上海▲シン▼湾生物科技有限公司 低酸素トリガーの人工転写因子、転写制御システム及びその応用
US20250319126A1 (en) * 2021-10-29 2025-10-16 Shanghai Sinobay Biotechnology Co., Ltd. Condition-controlled spliceable chimeric antigen receptor molecule and application thereof
CN114149510B (zh) * 2021-10-29 2024-01-30 上海鑫湾生物科技有限公司 一种条件控制的可剪接嵌合抗原受体分子及其应用
US20230227779A1 (en) * 2022-01-19 2023-07-20 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
WO2025255080A1 (en) * 2024-06-04 2025-12-11 The Children's Hospital Of Philadelphia Hypoxia inducible high-fidelity circuit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106559A1 (en) * 2002-02-01 2005-05-19 Philippa Radcliffe Viral vector
WO2012046943A2 (ko) * 2010-10-08 2012-04-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
US20160017048A1 (en) * 2013-03-07 2016-01-21 Baylor College Of Medicine Targeting cd138 in cancer
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
CN109280086A (zh) * 2018-09-10 2019-01-29 上海市公共卫生临床中心 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
JP2002526083A (ja) * 1998-09-23 2002-08-20 オックスフォード バイオメディカ（ユーケイ）リミテッド ポリヌクレオチド構築物およびその使用
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
GB0816096D0 (en) 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
BR112013003647A2 (pt) 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106559A1 (en) * 2002-02-01 2005-05-19 Philippa Radcliffe Viral vector
WO2012046943A2 (ko) * 2010-10-08 2012-04-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
US20160017048A1 (en) * 2013-03-07 2016-01-21 Baylor College Of Medicine Targeting cd138 in cancer
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
CN109280086A (zh) * 2018-09-10 2019-01-29 上海市公共卫生临床中心 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDRE JUILLERAT ET AL.: "An oxygen sensitive self-decision making engineered CAR T-cell", SCIENTIFIC REPORTS, vol. 71, pages 1 - 8 *
BITA JAVAN AND MAJID SHAHBAZI: "Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy", ECANCER, vol. 11, no. 6, pages 1 - 10 *
HYUN AH KIM ET AL.: "Transcriptional and post-translational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain", JOURNAL OF CONTROLLED RELEASE, vol. 121, no. 3, pages 218 - 22 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025016333A1 (zh) * 2023-07-14 2025-01-23 广州百吉生物制药有限公司 一种工程化免疫细胞及其制备和应用
WO2026016166A1 (zh) * 2024-07-19 2026-01-22 上海鑫湾生物科技有限公司 一种响应缺氧环境的差异化基因表达调控系统及其应用
CN119491023A (zh) * 2024-12-03 2025-02-21 北京再生世纪生物科技有限公司 一种基因修饰增强脐带间充质干细胞旁分泌功能的方法及其应用

Also Published As

Publication number Publication date
IL285587A (en) 2021-09-30
KR20210132105A (ko) 2021-11-03
AU2020224373A1 (en) 2021-08-26
EP3927734A1 (en) 2021-12-29
WO2020169974A1 (en) 2020-08-27
GB201902277D0 (en) 2019-04-03
JP2022520285A (ja) 2022-03-29
JP7684692B2 (ja) 2025-05-28
CA3130688A1 (en) 2020-08-27
US20220195009A1 (en) 2022-06-23
BR112021016435A2 (pt) 2022-01-18
AU2020224373B2 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
JP7527049B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP7684692B2 (ja) 低酸素応答性キメラ抗原受容体
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
JP7822340B2 (ja) キメラ抗原受容体およびその使用
JP7217970B2 (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
JP6942059B2 (ja) クローディン−１８．２−特異的免疫受容体およびｔ細胞エピトープ
US9272002B2 (en) Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US20210214415A1 (en) Immunoresponsive cells expressing dominant negative fas and uses thereof
JP2021176321A (ja) 養子細胞療法用の操作された細胞
JP2020195393A (ja) 養子細胞療法用の操作された細胞
US20210079057A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
JP2020537515A (ja) Ｈｐｖ特異的結合分子
WO2019047932A1 (zh) 基因工程化的t细胞及应用
CA2999070A1 (en) Car t cell therapies with enhanced efficacy
AU2019312358A1 (en) Compositions and methods for TCR reprogramming using target specific fusion proteins
WO2025225648A1 (ja) がんを処置するための組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination